
Opinion|Videos|August 6, 2024
FDA Approved Treatments: Topical Ruxolitinib and Vitiligo Management
Author(s)Andrea Rosik, PA-C
Advertisement
Episodes in this series

Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Auricular Acupuncture for Facial Rejuvenation: Results from a Large Real-World Clinical Series
2
Sun Pharma’s Cosibelimab-ipdl (UNLOXCYT) Enters US Market for Advanced CSCC
3
Lebrikizumab Enters Late-Stage Testing for Nummular Eczema
4
Graham Heap, MBBS, PhD, Discusses Positive Phase 3 Results for Zasocitinib
5



















